نتائج البحث - Eric O’Brien

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation

    The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation حسب Benjamin Mizukawa, Eric O’Brien, Daniel C. Moreira, Mark Wunderlich, Cindy L. Hochstetler, Xin Duan, Wei Liu, Emily Orr, H. Leighton Grimes, James C. Mulloy, Yi Zheng

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia

    Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia حسب Yasutaka Hayashi, Susumu Goyama, Xiaoxiao Liu, Moe Tamura, Shuhei Asada, Yosuke Tanaka, Tomofusa Fukuyama, Mark Wunderlich, Eric O’Brien, Benjamin Mizukawa, Satoshi Yamazaki, Akiko Matsumoto, Satoshi Yamasaki, Tatsuhiro Shibata, Koichi Matsuda, Goro Sashida, Hitoshi Takizawa, Toshio Kitamura

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Overcoming adaptive therapy resistance in AML by targeting immune response pathways

    Overcoming adaptive therapy resistance in AML by targeting immune response pathways حسب Katelyn Melgar, Morgan M. Walker, LaQuita M. Jones, Lyndsey Bolanos, Kathleen Hueneman, Mark Wunderlich, Jian-kang Jiang, Kelli M. Wilson, Xiaohu Zhang, Patrick Sutter, Amy Wang, Xin Xu, Kwangmin Choi, Gregory J. Tawa, Donald L. Lorimer, Jan Abendroth, Eric O’Brien, Scott B. Hoyt, Ellin Berman, Christopher Famulare, James C. Mulloy, Ross L. Levine, John P. Perentesis, Craig J. Thomas, Daniel T. Starczynowski

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

    MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199 حسب Juliana M. Benito, Laura Godfrey, Kensuke Kojima, Leah J. Hogdal, Mark Wunderlich, Huimin Geng, Isabel Marzo, Karine G. Harutyunyan, Leonard S. Golfman, Phillip North, Jon Kerry, Erica Ballabio, Triona Ní Chonghaile, Óscar Gonzalo, Yihua Qiu, Irmela Jeremias, LaKiesha Debose, Eric O’Brien, Helen Ma, Ping‐Kun Zhou, Rodrigo Jácamo, Eugene Park, Kevin R. Coombes, Nianxiang Zhang, Deborah A. Thomas, Susan O’Brien, Hagop M. Kantarjian, Joel D. Leverson, Steven M. Kornblau, Michael Andreeff, Markus Müschen, Patrick A. Zweidler‐McKay, James C. Mulloy, Anthony Letai, Thomas A. Milne, Marina Konopleva

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: